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Background: Glypican-3 (GPC3) is an oncofetal protein which is encoded by GPC3 gene and takes role in the
regulation of cell division and apoptosis. Overexpression of GPC3 has been reported in some types of cancer
such as hepatocellular carcinoma (HCC), melanoma, squamous cell carcinoma of the lungs and testicular germ
cell tumors. The aim of this study was to investigate the immunohistochemical expression of GPC3 in the
non-neoplastic urothelium and in urothelial carcinoma (UC). We also aimed to explore the alterations in the GPC3
expression according to the grade and the invasiveness of UC.
Methods: GPC3 expression was studied in 108 UC cases by using immunohistochemistry. Each section was
evaluated in terms of the extensiveness and intensity of GPC3 staining. Scores of immunostaining were correlated
with tumor grade and stage.
Results: GPC3 expression was observed in 38 cases (35.2%). GPC3 expression was positive in 43.6% of high and in
13.3% of low grade UC (p: 0.003). In 19 UC cases biopsy also harbored non-neoplastic urothelium which showed no
staining for GPC3. The difference in staining percentages between low and high grade UCs, suggests that GPC3
staining could be used as an adjunctive marker in cases where the distinction between the low and high grade
tumors is difficult. In addition, lack of staining in the non-neoplastic urothelial areas in 19 cases raises the possibility
of the use of GPC3 staining for the distinction between neoplastic and non-neoplastic urothelium, especially in
punch biopsy samples.
Conclusions: Based on our results potential role of GPC3 in urothelial carcinogenesis warrants further investigation,
especially the potential use of GPC3 for therapeutic and diagnostic purposes.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/2260833001522844
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GPC3 is a cellular surface heparan sulphate proteoglycan
which binds to the cell membrane through glycosylpho-
sphatidylinositol anchors [1]. The gene which codes GPC3
is localized in Xq26. GPC3 regulates cell growth and apop-
tosis by interacting with various morphogenic or growth
factors such as Wnt, fibroblast growth factor-2 and bone
morphogenic protein [2-4].
GPC3 expression, which is abundant during embryo-
genesis, is silent in most of adult tissues and therefore it* Correspondence: uzaydin@yahoo.com
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sion of GPC3 has been reported in some types of cancer
such as HCC, melanoma, squamous cell carcinoma of
the lungs and testicular germ cell tumors [8,9].
In HCC, GPC3 stimulates canonical Wnt signaling
and enhances in vitro and in vivo tumoral growth. GPC3
is also widely accepted as a tumor marker for HCC [10].
In preliminary studies, GPC3 derived peptide vaccines
had favorable effects on the survival in HCC cases
[11,12]. Dysregulation of Wnt signaling is proposed to
play a key role in the development of UC [13]. It has
been demonstrated that Wnt signal was activated in one
third of UC samples [14,15]. Therefore, investigation of
the role of GPC3 in UC would be interesting both forhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 GPC3 staining in UC according to grade and
invasion
Grade No staining Staining X2 P
N % N %
Low Grade 26 86.7 4 13.3 8.70 0.003
High Grade 44 56.4 34 43.6
Invasion
Non invasive 31 73.8 11 26.2 2.44 0.118
Invasive 39 59.1 27 40.9
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cinogenesis and in terms of demonstration the potential
of GPC3 overexpression as a therapeutic target.
In this study we aimed to investigate expression of
GPC3 in the non-neoplastic urothelium and in UC by
using immunohistochemical methods and to define the
alterations in the expression of GPC3 according to grade
and invasiveness of tumors.
Methods
Tissue samples from 108 urothelial carcinoma patients
treated in Ondokuz Mayis University Faculty of Medicine
between November 2012 and November 2013 were retro-
spectively analyzed in the pathology department of the in-
stitution. Samples of 86 transurethral resections, 12 radical
cystoprostatectomies, 7 nephrouretherectomies, and 3 blad-
der punch biopsies were included in the study. Eleven of
the patients were female and 97 were male; the mean age
was 68.4 (range 43–92) years. Hematoxylin-eosin sections
were re-evaluated and classified according to WHO/ISUP
(2004) and staged according to TNM (2009). Informed
consent regarding data collection for academic purposes
was obtained in all patients. The cases were categorized
into 4 major groups as low grade non-invasive, low grade
invasive, high grade non-invasive and high grade invasive.
Immunohistochemistry
All sections were examined, and the block that was most
representative of the tumor was selected. Four micrometer-
thick sections were taken, and immunohistochemical
examination was performed with a monoclonal mouse
antibody against human GPC3 (1:200, Clone IG12; Cell
Marque, Burlington, VT, USA). A standard immunohis-
tochemical technique was performed using a Ventana
Benchmark® XT autostainer (Ventana Medical Systems
Inc., Tucson, AZ, USA). Appropriate positive and nega-
tive controls were included for each run.
Each section was evaluated in terms of the extensiveness
and intensity of GPC3 staining. Extensiveness of staining
distribution was assessed as percentage of stained cells
and was recorded as multiples of ten. A staining percent-
age ≥ 10% was considered as positive. Staining extensive-
ness was scored as (1) when 10–50% of the cells were
stained, and (2) when > 50% was stained.
GPC3 staining intensity was evaluated only in positive
cases and scored as (1) for faint staining (light yellow), (2)
for moderate staining (brown), and (3) for strong staining
(dark brown). Combined scores were obtained by adding
of the intensity and extensiveness scores. Combined score
was considered as 0 in the negative cases [16].
Statistical analysis
The statistical analysis of differences in immunohisto-
chemical staining patterns between groups was performedusing Chi square test. Kruskal-Wallis variance test was
used in comparison of the scores. Bonferroni-corrected
Mann–Whitney U test was applied for post hoc binary
comparisons. The data was analyzed by the Statistical
Package for Social Sciences (SPSS for Windows, version
15.0; SPSS Inc., Chicago, IL). All statistical analyses
were two-sided, and p < 0.05 was considered statistically
significant.Results
Sixty six (61.1%) of the cases were evaluated as invasive,
42 (38.9%) as non-invasive; 78 (72.2%) as high grade and
30 (27.8%) as low grade UC. All of the low-grade cases
were non-invasive, while 66 (84.6%) of the high grade cases
were invasive and 12 (15.4%) cases were non-invasive
(Table 1).
Positive staining was observed in 38 (35.2%) cases.
Staining percentages were 43.6% in high and 13.3% in
low-grade UCs. No staining was detected in the non neo-
plastic urothelium in 19 cases containing non-neoplastic
urothelium in the non-tumoral areas.
Percentage of positive staining was found to be signifi-
cantly higher in high grade than in low grade UC (X2:
8.70; p: 0.003). Although positive staining was higher in in-
vasive UCs compared to non-invasive UCs, the difference
did not reach statistical significance (X2: 2.44; p: 0.118).
All the extensiveness and intensity scores and combined
scores were significantly higher in high grade compared to
the low grade UCs (p: 0.004, p: 0.027, p: 0.042, respect-
ively) (Table 2) (Figures 1, 2 and 3).
Extensiveness, intensity and combined scores of GPC3
staining was higher in invasive than in non-invasive UCs,
but the difference was not statistically significant (Table 3).
In the variance analysis carried out in order to test the
extensiveness, intensity and combined scores among the
groups; a statistically significant difference was found in
terms of each three scores (extensiveness score: F: 8.63,
p: 0.013; intensity score: F: 9.06, p: 0.011; combined score
F: 8.3, p: 0.015). Post-hoc analyzes revealed that the positiv-
ity, and the intensity of staining for GPC3 were statistically
significantly increased in high grade tumors regardless of
the invasiveness of the tumor.
Table 2 The relationship between the tumor grade and
GPC3 staining scores in UC
Extensiveness
score
Low Grade High Grade X2 P
N % N %
0 26 86.7 44 56.4 11.2 0.004
1 2 6.7 31 39.7
2 2 6.7 3 3.9
Intensity score
0 26 86.7 44 56.4 9.2 0.027
1 1 3.3 4 5.1
2 1 3.3 17 21.8
3 2 6.7 13 16.7
Combined score
0 26 86.7 44 56.4 9.88 0.042
1 0 0.0 0 0.0
2 0 0.0 4 5.1
3 1 3.3 16 20.5
4 3 10.0 12 15.4
5 0 0.0 2 2.6
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Glypican mediated regulation of signaling requires
receptor-ligand interaction and glypicans acts as a stimu-
lator or inhibitory effect on signaling activity [17]. Glypi-
cans also take part in Wnt formation [18,19]. GPC3 is
widely expressed during development and is downregu-
lated in most adult tissues [5]. Besides being a tumor
marker in hepatocellular carcinomas, GPC3 also plays a
role in development and progression and of HCC [10].
Capurro et al. [10], examined the ectopic effect of GPC3Figure 1 GPC3 staining in high grade invasive UC, with a combined scoreon various cell lines and demonstrated that GPC3 stimu-
lates canonical Wnt signaling, which promotes in vivo and
in vitro HCC growth. Activation of this pathway induces
cytosolic accumulation and nuclear translocation of tran-
scription factor β-catenin. In nucleus β-catenin is associ-
ated with the members of LEF/TCF transcription factors
and induces progression of cell cycle and expression of
the genes which stimulate cellular survival [20]. Canonical
Wnt activity has been shown to play a role in progression
of many cancer types including hepatocellular carcinoma
[20,21]. For example, Wnt is active in 90% of the patients
with colorectal cancer due to mutations in APC and β-
catenin genes, but mutations in these genes are rare in
HCC patients despite the fact of existence of the canonical
Wnt signal resulting in cytosolic and nuclear accumula-
tion of β-catenin in HCC [22-24]. Thus, overexpression of
GPC3 reflects an alternative mechanism in which Wnt ac-
tivity is stimulated in HCC [25,26]. As in hepatocellular
carcinomas, Wnt pathway may be activated by GPC3 in
the positive UC cases.
To our knowledge, there are a few studies about GPC3
expression in urothelial carcinomas and normal urothe-
lium [6,27,28]. For example, Baumhoer et al. [6] examined
GPC3 expression in the invasive urothelial carcinomas of
the bladder using microarray method. They found a posi-
tive staining in 7 (16%) of 43 cases. No staining was ob-
served in the normal bladder urothelium. Gailey et al. [27]
observed a positive staining for GPC3 in 6 of 49 (12.2%)
UC. In both studies, there was no information about the
grade and the invasiveness of the tumor. Therefore our
study is probably the first study investigating the relation-
ship between GPC3 expression, and the grade and the in-
vasiveness of UCs.5 (immunoperoxidase, x200 magnification).
Figure 2 GPC3 staining in high grade non-invasive papillary UC, with a combined score 4 (immunoperoxidase, x200 magnification).
Figure 3 GPC3 staining in low grade non-invasive papillary UC, with
a combined score 3 (immunoperoxidase, x200 magnification).
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ical cystectomy material. In addition 50 tumor adjacent
normal bladder samples were studied as controls. They
observed positive staining in 19 (6%) of urothelial car-
cinomas. The authors underlined that there was no
GPC3 expression in benign urothelium.
In our study, GPC3 expression was higher compared
to the results obtained in the studies of Baumhoer et al.,
Gailey et al. and Xylinas et al. [6,27,28]. This is likely
caused by the differences in immunostaining techniques.Table 3 Correlation between invasiveness and GPC3
staining scores in UC
Extensiveness
score
Non invasive Invasive X2 P
N % N %
0 31 73.8 39 59.1 4.77 0.092
1 8 19.1 25 37.9
2 3 7.1 2 3.0
Intensity score
0 31 73.8 39 59.1 2.74 0.434
1 2 4.8 3 4.5
2 5 11.9 13 19.7
3 4 9.5 11 16.7
Combined score
0 31 73.8 39 59.1 4.15 0.386
1 0 0.0 0 0.0
2 1 2.4 3 4.5
3 4 9.5 13 19.7
4 6 14.3 9 13.7
5 0 0.0 2 3.0
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when tissue microarrays with small tissue sections are
used [6]. The sizes of the study populations may be an-
other factor. Considering the small number of studies on
UCs, more extensive studies including more cases are
needed for clarification of the GPC3 expression status
and its role in UC. In accordance with the results of the
previous studies we did not observe staining in the non-
neoplastic urothelium.
Grading and staging of urothelial carcinomas are import-
ant since clinical approach changes accordingly. Amongst
the non-muscle invading tumors (stages T0-carcinoma in
situ and T1) high grade tumors are considered in high
risk group. Low risk patients (primary, solitary, Ta, low
grade, < 3 cm) will not be treated with adjuvant intrave-
sical BCG, whereas high risk patients will [29]. The dif-
ference in staining percentages in low (13.3%) and high
grade (43.6%) UCs, suggests that GPC3 staining could
be used as an adjunctive marker in cases where the dis-
tinction between the low and high grade tumors is diffi-
cult. Even more, lack of staining in the benign urothelial
areas in 19 cases containing non-neoplastic urothelium,
raises the possibility of the use of GPC3 staining for the
distinction between neoplastic and non-neoplastic urothe-
lium, especially in punch biopsy samples.
Studies indicate that GPC3 is a promising molecule in
immunotherapy [26]. Nakatsura et al. demonstrated in
the transgenic rats that GPC3 peptide vaccine induced
peptide reactive cytotoxic T lymphocytes without produ-
cing autoimmunity. Nakatsura et al. conducted phase 1
clinic trial of a vaccine composed of two GPC3-derived
peptides and incomplete Freund adjuvant in advanced
HCC patients. The vaccine elicited immune response
in the majority of the patients and the level of the im-
mune response was in correlation with the overall sur-
vival [11,12,26].
GPC3 expression defined in urothelial carcinomas sug-
gested that GPC3-derived vaccines might have an immu-
notherapeutic effect on these tumors.Conclusion
In conclusion, in our study GPC3 was expressed in a
significant proportion of urothelial carcinomas, mostly
in the high grade tumors. GPC3 staining may be useful
in differentiating between non-neoplastic and neoplastic
urothelium as well as high grade and low grade urothelial
carcinoma especially in small punch biopsies. Potential role
of GPC3 in urothelial carcinogenesis warrants further in-
vestigation, especially the potential use of GPC3 for thera-
peutic and diagnostic purposes.Competing interests
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